title: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones.
abstract: BACKGROUND
  Four cardiac hormones have anticancer effects in vitro: i) atrial natriuretic peptide (ANP), ii) vessel dilator, iii) long acting natriuretic peptide (LANP), and iv) kaliuretic peptide.
  
  
  METHODS
  These cardiac hormones were infused subcutaneously for 28 days with weekly fresh hormones at 3 nM min(-1) kg(-1) body weight in athymic mice bearing human pancreatic adenocarcinomas.
  
  
  RESULTS
  ANP, vessel dilator, LANP and kaliuretic peptide eliminated 80%, 33%, 20% and 14% of the pancreatic adenocarcinomas. Even in the treated animals which did not have a total cure, their tumor volume decreased to less than 10% (and with vessel dilator to 2%) of that of the untreated animals. The natriuretic peptide receptor (NPR)-A receptor was decreased 33% to 55% in the metastatic lesions compared to the primary pancreatic adenocarcinoma.
  
  
  CONCLUSIONS
  Four cardiac hormones eliminated up to 80% of human pancreatic adenocarcinomas in athymic mice.
authors.affiliation: Department of Internal Medicine, University of South Florida Cardiac Hormone Center, and James A. Haley Veterans Medical Center, Tampa, FL, USA. david.vesely@med.va.gov
authors.forename: David L
authors.initials: DL
authors.lastname: Vesely
authors.forename: Ehrentraud J
authors.initials: EJ
authors.lastname: Eichelbaum
authors.forename: Ying
authors.initials: Y
authors.lastname: Sun
authors.forename: Abdel A
authors.initials: AA
authors.lastname: Alli
authors.forename: Brian A
authors.initials: BA
authors.lastname: Vesely
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Luther
authors.forename: William R
authors.initials: WR
authors.lastname: Gower
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000188:drug therapy* / Q000556:secondary; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D006162:Guanylate Cyclase / Q000378:metabolism; D006801:Humans; D007279:Injections, Subcutaneous; D051379:Mice; D008819:Mice, Nude; D045265:Natriuretic Peptides / Q000494:pharmacology*; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D010446:Peptide Fragments / Q000494:pharmacology; D011498:Protein Precursors / Q000494:pharmacology; D017461:Receptors, Atrial Natriuretic Factor / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D045265:Natriuretic Peptides; D010446:Peptide Fragments; D011498:Protein Precursors; C075322:atrial natriuretic factor precursor (79-98); C054547:atrial natriuretic factor prohormone (1-30), human; D009320:Atrial Natriuretic Factor; D006162:Guanylate Cyclase; D017461:Receptors, Atrial Natriuretic Factor; C091715:atrial natriuretic factor receptor A